First Header Logo Second Header Logo

Connection

Thomas Wierzba to Diarrhea

This is a "connection" page, showing publications Thomas Wierzba has written about Diarrhea.
Connection Strength

4.491
  1. Barry E, Cassels F, Riddle M, Walker R, Wierzba T. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine. 2019 08 07; 37(34):4768-4774.
    View in: PubMed
    Score: 0.792
  2. Wierzba TF. Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Vaccine. 2019 08 07; 37(34):4775-4777.
    View in: PubMed
    Score: 0.792
  3. Wierzba TF, Muhib F. Exploring the broader consequences of diarrhoeal diseases on child health. Lancet Glob Health. 2018 03; 6(3):e230-e231.
    View in: PubMed
    Score: 0.717
  4. Wierzba TF, Bourgis A. Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016. Vaccine. 2017 01 23; 35(4):503-507.
    View in: PubMed
    Score: 0.661
  5. Desai SN, Sahastrabuddhe S, Ochiai RL, Wierzba TF. Enteric vaccines for resource-limited countries: current status and future prospects. Pediatr Ann. 2011 Jul; 40(7):351-7.
    View in: PubMed
    Score: 0.452
  6. Wierzba TF, Abdel-Messih IA, Abu-Elyazeed R, Putnam SD, Kamal KA, Rozmajzl P, Ahmed SF, Fatah A, Zabedy K, Shaheen HI, Sanders J, Frenck R. Clinic-based surveillance for bacterial- and rotavirus-associated diarrhea in Egyptian children. Am J Trop Med Hyg. 2006 Jan; 74(1):148-53.
    View in: PubMed
    Score: 0.309
  7. Anderson JD, Bagamian KH, Muhib F, Amaya MP, Laytner LA, Wierzba T, Rheingans R. Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis. Lancet Glob Health. 2019 03; 7(3):e321-e330.
    View in: PubMed
    Score: 0.192
  8. Abdel-Messih IA, Wierzba TF, Abu-Elyazeed R, Ibrahim AF, Ahmed SF, Kamal K, Sanders J, Frenck R. Diarrhea associated with Cryptosporidium parvum among young children of the Nile River Delta in Egypt. J Trop Pediatr. 2005 Jun; 51(3):154-9.
    View in: PubMed
    Score: 0.073
  9. Rao MR, Wierzba TF, Savarino SJ, Abu-Elyazeed R, El-Ghoreb N, Hall ER, Naficy A, Abdel-Messih I, Frenck RW, Svennerholm AM, Clemens JD. Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea. J Infect Dis. 2005 Feb 15; 191(4):562-70.
    View in: PubMed
    Score: 0.072
  10. Shaheen HI, Khalil SB, Rao MR, Abu Elyazeed R, Wierzba TF, Peruski LF, Putnam S, Navarro A, Morsy BZ, Cravioto A, Clemens JD, Svennerholm AM, Savarino SJ. Phenotypic profiles of enterotoxigenic Escherichia coli associated with early childhood diarrhea in rural Egypt. J Clin Microbiol. 2004 Dec; 42(12):5588-95.
    View in: PubMed
    Score: 0.072
  11. Putnam SD, Frenck RW, Riddle MS, El-Gendy A, Taha NN, Pittner BT, Abu-Elyazeed R, Wierzba TF, Rao MR, Savarino SJ, Clemens JD. Antimicrobial susceptibility trends in Campylobacter jejuni and Campylobacter coli isolated from a rural Egyptian pediatric population with diarrhea. Diagn Microbiol Infect Dis. 2003 Dec; 47(4):601-8.
    View in: PubMed
    Score: 0.067
  12. Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I, Shaheen H, Frenck RW, Svennerholm AM, Clemens JD. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. J Clin Microbiol. 2003 Oct; 41(10):4862-4.
    View in: PubMed
    Score: 0.066
  13. Walker RI, Wierzba TF, Mani S, Bourgeois AL. Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine. 2017 12 14; 35(49 Pt A):6775-6782.
    View in: PubMed
    Score: 0.044
  14. Bourgeois AL, Wierzba TF, Walker RI. Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 2016 06 03; 34(26):2880-2886.
    View in: PubMed
    Score: 0.039
  15. Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016 06 03; 34(26):2887-2894.
    View in: PubMed
    Score: 0.039
  16. Ali M, You YA, Sur D, Kanungo S, Kim DR, Deen J, Lopez AL, Wierzba TF, Bhattacharya SK, Clemens JD. Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design. Vaccine. 2016 Jan 20; 34(4):479-485.
    View in: PubMed
    Score: 0.038
  17. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013 Dec; 13(12):1050-6.
    View in: PubMed
    Score: 0.033
  18. Clemens J, Savarino S, Abu-Elyazeed R, Safwat M, Rao M, Wierzba T, Svennerholm AM, Holmgren J, Frenck R, Park E, Naficy A. Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. J Infect Dis. 2004 Jun 15; 189(12):2299-307.
    View in: PubMed
    Score: 0.017
  19. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF, Abu-Elyazeed R, Rao M, Francis WM, El Mohamady H, Safwat M, Naficy AB, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J. 2002 Apr; 21(4):322-30.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.